Do Peptides Cause Cancer? The Real Risk Explained

The question of whether peptides cause cancer usually gets answered in one of two ways: either with a flat "no, there's no evidence" or with a vague warning that shuts the conversation down before it starts. Neither answer actually explains the mechanism, and without the mechanism, you have no way to evaluate your own risk.

So start with the system.

Your body runs on signaling. Hormones, peptides, and growth factors are essentially messages that travel between cells and tell them what to do, and one of the most important things those messages can tell a cell is to divide and multiply. That process is called cell proliferation, which is just the biological term for cells copying themselves, and it is not inherently dangerous. It is how you heal a wound, how you build muscle, how your gut lining replaces itself every few days.

The growth hormone axis is one of the main systems that drives this signaling. The chain works like this: the hypothalamus releases something called GHRH, which stands for growth hormone releasing hormone, and that signal travels to the pituitary gland and tells it to secrete growth hormone into the bloodstream. Growth hormone then travels to the liver, where it triggers the production of something called IGF-1, which stands for insulin-like growth factor 1, and IGF-1 is the molecule that actually goes into tissues and stimulates cells to grow and repair.

Most of the peptides people use in performance and longevity contexts, things like CJC-1295, ipamorelin, or sermorelin, work somewhere in this chain. They are either mimicking GHRH or stimulating the pituitary through a slightly different receptor pathway, and the end result is more growth hormone and more IGF-1 circulating in the body.

That is the map. Now here is where the cancer question comes in.

Cancer is not a single event. It is a process. A cell accumulates mutations over time, escapes the normal checkpoints that would trigger it to self-destruct, and begins dividing without the usual restraint. Once a tumor is established, it is still made of cells, and those cells still carry receptors for growth signals, including IGF-1 receptors.

This is the actual concern with growth hormone related peptides, and it is a legitimate one. It is not that these peptides mutate DNA or create cancer from nothing. There is currently no data showing that. The concern is what happens if a tumor already exists, even a small one that has not been detected yet. If you are introducing signals that promote cellular proliferation throughout your body, you are not sending those signals only to your muscle cells or your joints. You are sending them everywhere, and that includes any abnormal cells that happen to be present.

Think of it like this. Imagine your body is a city, and IGF-1 is a general announcement over the loudspeaker telling everyone to get to work and build. Most of the workers in that city are doing legitimate jobs. But if there is a group operating illegally somewhere in the city, they hear the same announcement and they start working too. The signal does not discriminate.

This is why the warning exists on most protocols, and the warning is scientifically grounded. But the warning is often interpreted as meaning the peptides themselves cause cancer, which is not what the evidence says.

There is actually research showing something more nuanced happening at the receptor level. Studies looking at ghrelin receptor signaling, which is the pathway that ghrelin mimetics like ipamorelin use, have found that in some cancer cell lines the receptor is actually silenced through a process called DNA methylation, which is when a gene gets chemically tagged in a way that turns it off. One study looking at thymic carcinoma found that the ghrelin receptor gene was among the most commonly methylated genes in that cancer type, suggesting the tumor had downregulated that signaling pathway rather than being driven by it. That is the opposite of what a simple "growth signal causes cancer" story would predict, and it illustrates why this is not a clean one-direction relationship.

The breast cancer data is similarly complicated. Research from the European Prospective Investigation into Cancer and Nutrition looked at genetic variants in the genes coding for ghrelin and its receptor across thousands of women and examined whether those variants predicted breast cancer risk. The associations found were modest and context-dependent, not the kind of clear dose-response relationship you would expect if ghrelin signaling were a primary driver of cancer initiation.

What the evidence does support is a promotion model rather than an initiation model. IGF-1 does not appear to create cancer. It may accelerate the growth of cancer that is already developing. And that distinction matters enormously when thinking about who should actually be concerned.

For someone with an active cancer diagnosis, or a cancer that has been treated but may have residual disease, using peptides that elevate IGF-1 is a real consideration to work through with an oncologist. The math there is straightforward: you do not want to add a proliferation signal to a system that already has uncontrolled proliferation happening somewhere.

For someone with no personal history of cancer, no current diagnosis, and no strong family history that would suggest elevated baseline risk, the theoretical concern is that you might have a microscopic tumor you do not know about and you might be providing a favorable environment for it to grow faster. That risk cannot be reduced to zero, because biology does not work that way. But the baseline rate of undetected cancer in any given person at any given moment is low, the magnitude of IGF-1 increase from physiological doses of these peptides is modest compared to the variation you see across healthy individuals naturally, and there is no human longitudinal data showing elevated cancer incidence in people who have used these peptides.

The practical starting point is simple. If you have cancer or a strong reason to suspect you might, this is not the place to start. Get imaging, talk to a physician who understands both oncology and this space, and make a decision with actual information about your situation.

If you are a healthy person with no red flags, you are making a decision under uncertainty, which is true of almost every intervention. The uncertainty here is real, but the magnitude of it is proportionate to your actual baseline risk.

The thing worth sitting with is this: the warning that peptides "may promote tumor growth" and the claim that peptides "cause cancer" are not the same statement. One is a mechanistic caution about a specific scenario. The other is a causal claim that the evidence simply does not support. Collapsing those two into the same warning is how a legitimate scientific concern becomes a reason people either panic unnecessarily or dismiss the concern entirely, and neither response serves you.

---

References

1. Schally AV, Comaru-Schally AM, Plonowski A et al.. Peptide analogs in the therapy of prostate cancer. Prostate. 2000. Source
2. George DJ, Dearnaley DP. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. Future Oncol. 2021. Source
3. Krakowsky Y, Morgentaler A. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. Eur Urol Focus. 2019. Source
4. Deng G, Zeng F, Su J et al.. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020. Source
5. Zhang X, Zhang Y, He Z et al.. Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2. Cell Death Dis. 2019. Source
6. Wu J, Gonzalez Castro LN, Battaglia S et al.. Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas. Nat Cancer. 2025. Source
7. Kishibuchi R, Kondo K, Soejima S et al.. DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma. Int J Oncol. 2020. Source
8. Dossus L, McKay JD, Canzian F et al.. Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition EPIC. Carcinogenesis. 2008. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness